About three-quarters of users in each group 77% of those taking compounded or custom-mixed medications and 74% of those taking brand-name drugs said the treatments are either "effective" or "extremely effective." Compounded GLP-1 users were slightly more likely to rate the medications as "extremely effective," with 39% reporting that level of effectiveness compared with 32% of brand-name medication users
Lancet Diabetes Endocrinol, 7(5), 356-367
(The primary ingredient in the GLP-1 shots is semaglutide, an ingredient that is not present in the patches.) When reached for comment, a representative for Kind Patches said that though they stood behind their product, they may not be universally effective
Among the most notable additions are the active ingredients in Novo Nordisks Ozempic and Eli Lillys Mounjaro, both GLP-1 receptor agonists originally developed for type 2 diabetes
Novo Nordisk and Hims & Hers reached a previous agreement last year that was supposed to bring down prices of Wegovy and Ozempic while tapering the telehealth provider's compounded offerings, but little came of it
